Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy data from its phase 2 trial with personalised cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in October 2026.

The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine's effect also when not administered in combination with anti-PD-1 therapy. The data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

Two-year data demonstrated an Objective Response Rate (ORR) of 75%, as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

Meanwhile, 54% of patients had a deepened response during treatment, improving from stable disease or partial response to partial or complete response. Tumour reduction (target lesions) was observed in 15 out of the 16 patients enrolled in the trial.

EVX-01 induced an immune response in all patients, with 86% of the targeted neoantigens generating potent specific T-cell responses.